Harrow shares are trading higher after the company announced the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. Also the company announced that the second and third required PPQ batches are now scheduled
Portfolio Pulse from Benzinga Newsdesk
Harrow shares are trading higher following the announcement of the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. The company also scheduled the second and third required PPQ batches.
June 20, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harrow shares are trading higher after the company announced the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. The scheduling of the second and third PPQ batches further boosts investor confidence.
The announcement of the successful manufacture of the first commercial-scale PPQ batch and the scheduling of the next two batches is a significant milestone for Harrow. This progress indicates that the company is on track with its production plans, which is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100